创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Luminex Platform Features in Detail

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-13 15:00
  • Views:

(Summary description)With the rapid development of life science technology, there is a growing demand for efficient, accurate and high-throughput biomolecular detection platforms for researchers. Against this backdrop, the Luminex platform of InnoModels Biotechnology has emerged and occupied a pivotal position in life science research with its unique advantages. In this article, we will analyze the features of the Luminex platform in detail, and reveal how it has revolutionized traditional biomolecular detection methods.

InnoModels Biotechnology: Luminex Platform Features in Detail

(Summary description)With the rapid development of life science technology, there is a growing demand for efficient, accurate and high-throughput biomolecular detection platforms for researchers. Against this backdrop, the Luminex platform of InnoModels Biotechnology has emerged and occupied a pivotal position in life science research with its unique advantages. In this article, we will analyze the features of the Luminex platform in detail, and reveal how it has revolutionized traditional biomolecular detection methods.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-13 15:00
  • Views:
Information

With the rapid development of life science technology, there is a growing demand for efficient, accurate and high-throughput biomolecular detection platforms for researchers. Against this backdrop, the Luminex platform of InnoModels Biotechnology has emerged and occupied a pivotal position in life science research with its unique advantages. In this article, we will analyze the features of the Luminex platform in detail, and reveal how it has revolutionized traditional biomolecular detection methods.
The core technology of the Luminex platform lies in the application of fluorescence-encoded magnetic beads/microspheres. These microspheres are fluorescently encoded to carry multiple antibodies or gene probes specific for different biomolecules at the same time. This design allows the Luminex platform to accurately quantify up to 2-500 different biomolecules in a single tube, greatly improving detection efficiency.
The platform integrates a variety of advanced technologies such as flow principles, laser analysis, and high-speed digital signal processing to realize parallel analysis of multiple indicators. Laser irradiation of the fluorescence on the magnetic beads can quickly identify the captured antibody labeled by the beads, and then determine the detection items corresponding to the beads. This design not only improves the accuracy of the test, but also makes the operation process easier, greatly reducing the experimental cost and time cost.

 


The Luminex platform offers significant advantages in assay performance. Measurement results are similar to those of traditional methods such as ELISA in terms of accuracy, precision, and sensitivity. In addition, the Luminex platform has a wider linear range, which further enhances the reliability of the assay results.
It is worth mentioning that the Luminex platform excels in multiplexed detection. By freely combining different fluorescence-encoded magnetic beads, researchers can analyze multiple target molecules simultaneously in a single experiment. This multi-detection capability not only reduces the consumption of biological samples, but also allows for more accurate analysis of correlations between multiple target molecules.
In addition, the Luminex platform has excellent application scalability. In addition to immunoassay, nucleic acid research, enzyme analysis, etc., the platform can also be applied to pathogen detection and typing, HLA typing, miRNA expression profiling, transcription factor research, and many other applications. This makes the Luminex platform have a wide range of application prospects in basic life science research and medical diagnostic technology development.
In conclusion, with its unique fluorescence-encoded magnetic bead technology, its ability to analyze multiple indicators in parallel, and its wide range of applications, InnoModels' Luminex platform has demonstrated strong competitiveness in the field of biomolecular testing. With the continuous development and improvement of the technology, it is believed that the Luminex platform will bring more breakthroughs and innovations to life science research and medical diagnosis in the future.   

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司